(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …
The current valuation of Biogen Inc’s (NASDAQ: BIIB) stock represents “a reasonable entry for the Alzheimer's and SMA franchises as well as a couple of other pipeline programs that seem interesting,” Piper Jaffray’s Joshua E. Schimmer …
Yesterday’s rumored M&A interest in Biogen Inc (NASDAQ:BIIB) spiked the stock 10% in a single day. Now that the euphoria has died down, let’s examine what a realistic takeover number might be. With both Merck and Allergan …
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here. Biogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the …
The Biogen Inc. (Nasdaq: BIIB) stock price was down about 6% this morning (Friday) after the company missed on Q1 earnings – but this slip won't last… Biogen reported earnings per share (EPS) of $3.82 compared to estimates of $3.91. …
The share price of Biogen Inc. (NASDAQ:BIIB) tumbled as much as 8 percent, to $395, Friday after sales of the …
Shares of Biogen Idec Inc (NASDAQ:BIIB) were up past 10% this morning during premarket ... Biogen has been on a bull run lately, with the stock up 36.50% year to date. Biotechnology continues to be a hot spot for investors, as the …
Biogen Idec Inc. (BIIB) was a big mover last session with shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company …